• Increase font size
  • Default font size
  • Decrease font size

Caraco drugs seized by U.S. authorities

Print E-mail
By Staff and Wire Reports   
Thursday, 25 June 2009 22:28

BioMedReports.com - Caraco drugs seized by U.S. authoritiesWASHINGTON (Reuters) - U.S. authorities have seized all medicines produced by generic drugmaker Caraco Pharmaceutical Laboratories Ltd (NYSE-Alt:CPD) following repeated violations of manufacturing standards, health officials said.

The drugs included generic versions of heart, pain and psychiatric medicines, Food and Drug Administration officials said on Thursday.

Up to 33 different drugs may have been seized at the company's three manufacturing plants, all located in Michigan. Drug ingredients also were being held.

After the news, Caraco shares fell 43 percent to $2.39 on the American Stock Exchange.

"This action follows Caraco's continued failure to meet" manufacturing standards that assure drug quality, an FDA statement said.

"Through this seizure, the FDA seeks to immediately stop the firm from further distributing drugs until there is assurance that the firm complies with good manufacturing requirements."

A Caraco spokesman could not immediately be reached for comment.

Consumers now taking medicines made by Caraco should not stop, FDA officials advised. Any defective drugs have come off the market in a series of recalls since January. Those recalls were related to defects such as oversized tablets and possible formulation errors, the agency said.

The company was warned about manufacturing problems in an FDA letter sent in October 2008, said FDA consumer safety officer David Jaworski. A May 2009 inspection found unresolved violations.

FDA inspectors found poor control of raw materials, higher- than-normal variability in tablet manufacturing processes and "poor decisions made by the company's management who are responsible for the quality of drugs being manufactured," Jaworski said.

The FDA said the seizure may create a shortage of one pain reliever, choline magnesium trisalicylate oral tablets. Patients should talk to their doctors about alternatives if supplies run short, agency officials advised. (Reporting by Lisa Richwine; editing by Steve Orlofsky and Andre Grenon)




BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 10 hours ago Watson Provides Update on Generic Lidoderm® Application; Gilead Soars On "Striking" Clinical Trial Data: Below i... http://t.co/IbLYNqgb
about 18 hours ago Shares of $IDIX drop slightly after compelling new data from rival Gilead ($GILD) puts prospects for IDIX's hepatitis C drug in question.
about 1 day ago Medgenics has Key to Protein Therapy Market: Medgenics (NASDAQ: MDGN) has what I believe to be the most disrupti... http://t.co/c3IBIWYR
about 1 day ago Stocks Vacillate To Mixed Finish; Some Leaders Rally http://t.co/dtOQTRgh
about 1 day ago Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk; FDA Approves JANUMET XR: Belo... http://t.co/a7IlIvbS
about 1 day ago Athersys $ATHX gets grant to study traumatic brain injury http://t.co/mnZTsxXx
about 1 day ago Watching: San Antonio patients help test new 'spray-on skin' for burns http://t.co/fzKA9B23
about 1 day ago OncoSec's President and CEO explains his firm's ambitious list of milestones for 2012: During the past few sessi... http://t.co/fKOMc1TM

navigation

Free Phone Trade Alerts